Search
Autolus Therapeutics PLC
AUTLAdd to Watchlist
1.490USD
-0.040-2.61%
Close 07-31 16:00（ET）Quotes delayed by 15 min
396.57MMarket Cap
LossP/E TTM
More Details of Autolus Therapeutics PLC Company
Autolus Therapeutics plc is a United Kingdom-based early commercial-stage biopharmaceutical company developing programmed T cell therapies for the treatment of cancer and autoimmune diseases. The Company has an approved commercial product, AUCATZYL, for the treatment of adult patients with r/r B-ALL. Using a suite of proprietary and modular T cell programming technologies, it is also developing five programs in seven hematological and solid tumor indications and one autoimmune indication. It is engineering precisely targeted, controlled and highly active T cell therapies that are designed to better recognize target cells, break down their defense mechanisms and attack and eliminate these cells. Its product pipeline includes obe-cel (ALLCAR19), obe-cel (CAROUSEL), AUTO1/22 (CARPALL), AUTO4 (LibrA T1), AUTO6 (MAGNETO), AUTO5, AUTO8 (MCARTY) and AUTO9. AUTO4 and AUTO5 are two programmed T cell therapies for the treatment of peripheral T-cell lymphoma targeting TRBC 1 and TRBC 2.
Autolus Therapeutics PLC Info
Ticker SymbolAUTL
Company nameAutolus Therapeutics PLC
IPO dateJun 22, 2018
CEOItin (Christian Martin)
Number of employees647
Security typeDepository Receipt
Fiscal year-endJun 22
AddressThe Mediaworks
CityLONDON
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited Kingdom
Postal codeW12 7FP
Phone442038296230
Websitehttps://www.autolus.com/
Ticker SymbolAUTL
IPO dateJun 22, 2018
CEOItin (Christian Martin)
Company Executives of Autolus Therapeutics PLC
Name
Name/Position
Position
Shareholding
Change
Ms. Cynthia M. Butitta
Ms. Cynthia M. Butitta
Non-Executive Independent Director
Non-Executive Independent Director
10.00K
--
Mr. Brent Rice
Mr. Brent Rice
Senior Vice President, Chief Commercial Officer
Senior Vice President, Chief Commercial Officer
9.40K
--
Dr. Christian Martin Itin, Ph.D.
Dr. Christian Martin Itin, Ph.D.
Chief Executive Officer, Executive Director
Chief Executive Officer, Executive Director
--
--
Mr. Martin Pule
Mr. Martin Pule
Founder, Senior Vice President, Chief Scientific Officer
Founder, Senior Vice President, Chief Scientific Officer
--
--
Mr. Christopher Vann
Mr. Christopher Vann
Chief Operating Officer, Senior Vice President
Chief Operating Officer, Senior Vice President
--
--
Mr. David Brochu
Mr. David Brochu
Senior Vice President, Chief Technical Officer
Senior Vice President, Chief Technical Officer
--
--
Mr. John Edward Berriman
Mr. John Edward Berriman
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Ms. Linda C. Bain
Ms. Linda C. Bain
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. William D. (Bill) Young, Ph.D.
Mr. William D. (Bill) Young, Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Dr. Elisabeth (Lis) Leiderman, M.D.
Dr. Elisabeth (Lis) Leiderman, M.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Ms. Cynthia M. Butitta
Ms. Cynthia M. Butitta
Non-Executive Independent Director
Non-Executive Independent Director
10.00K
--
Mr. Brent Rice
Mr. Brent Rice
Senior Vice President, Chief Commercial Officer
Senior Vice President, Chief Commercial Officer
9.40K
--
Dr. Christian Martin Itin, Ph.D.
Dr. Christian Martin Itin, Ph.D.
Chief Executive Officer, Executive Director
Chief Executive Officer, Executive Director
--
--
Mr. Martin Pule
Mr. Martin Pule
Founder, Senior Vice President, Chief Scientific Officer
Founder, Senior Vice President, Chief Scientific Officer
--
--
Mr. Christopher Vann
Mr. Christopher Vann
Chief Operating Officer, Senior Vice President
Chief Operating Officer, Senior Vice President
--
--
Mr. David Brochu
Mr. David Brochu
Senior Vice President, Chief Technical Officer
Senior Vice President, Chief Technical Officer
--
--
FAQs
Who are the top five shareholders of Autolus Therapeutics PLC?
The top five shareholders of Autolus Therapeutics PLC are: Ms. Cynthia M. Butitta
How many institutions hold shares of Autolus Therapeutics PLC (AUTL)?
As of 2026Q1, 239 institutions hold shares of Autolus Therapeutics PLC, with a combined market value of approximately 209.95M, accounting for 78.88% of the total shares. Compared to 2025Q4, institutional shareholding has increased by -50130311.00.